Shares of Myomo, Inc. (NASDAQ:MYO) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Analysts have set a 12-month consensus target price of $6.68 for the company and are forecasting that the company will post ($0.22) earnings per share for the current quarter, according to Zacks. Zacks has also given Myomo an industry rank of 99 out of 257 based on the ratings given to related companies.

Separately, Roth Capital reaffirmed a “buy” rating on shares of Myomo in a research note on Thursday, November 8th.

Shares of MYO stock traded down $0.01 on Friday, hitting $1.76. The company had a trading volume of 28,386 shares, compared to its average volume of 398,215. Myomo has a twelve month low of $1.60 and a twelve month high of $5.63.

Myomo (NASDAQ:MYO) last issued its quarterly earnings results on Monday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.82 million.

Myomo Company Profile

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with's FREE daily email newsletter.